AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06618469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic band-based resistance training program at high intensity (HI)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 85% of the one-repetition maximum per exercise (high load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
Study NCT06618469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic band-based resistance training program at moderate-high intensity (MHI-bands)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
Study NCT06618469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic band-based resistance training program at moderate intensity (MI)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 65-70% of the one-repetition maximum per exercise (moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
Study NCT06618469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic tubes equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase)
Study NCT01858480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: D-ribose powder for oral solution and D-ribose for injection.
Study NCT01858480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosage form designed to mock active.
Study NCT04278677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Melatonin capsules to be taken for 6 weeks
Study NCT02254083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - low
Study NCT06618469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based resistance training program at moderate intensity (WMI)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
Study NCT02254083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - high
Study NCT02254083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02133482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo solution
Study NCT02133482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 639667
Description: oral solution BI 639667, single rising doses
Study NCT00888758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biolimus A9
Description: 200 patients with STEMI will be treated using Biomatrix stent.
Study NCT00888758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: 200 patients with STEMI will be treated with PROMUS DES.
Study NCT01694810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% NVN1000 Topical Gel
Description: 2% NVN1000 Topical Gel once daily for 4 weeks
Study NCT01694810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% NVN1000 Topical Gel
Description: 4% NVN1000 4% Topical Gel applied once daily 4 weeks
Study NCT01694810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% NVN1000 Topical Gel
Description: 8% NVN1000 Topical Gel applied once daily for 4 weeks
Study NCT01694810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Topical Gel applied once daily
Study NCT03800979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
Study NCT02851966 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mTESE
Description: mTESE time may be postponed or advanced.
Study NCT01077479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1500mg nocte for 6 months
Study NCT00580996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water high dose
Description: water 16 oz PO x 1
Study NCT00580996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water tiny dose
Description: water 1 oz PO x 1
Study NCT00335725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: subcutaneous injection of FSH. Starting dose: 225 IU.
Study NCT00335725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: subcutaneous injection of FSH. Starting dose: 225 IU.
Study NCT01935921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01935921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01935921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01935921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01380886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental infant formula with alternate protein source
Description: experimental infant formula to be fed ad libitum
Study NCT01380886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula powder
Description: powdered infant formula to be fed ad libitum
Study NCT01024790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: 24 week group exercise class supplemented with behavioral activation strategies
Study NCT06622343 — intervention group
Intervention type: DRUG
Intervention: Antivenom Serum
Description: Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.
Study NCT06622343 — intervention group
Intervention type: PROCEDURE
Intervention: Wound Debridement
Description: Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.
Study NCT03101826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study NCT04000542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention
Description: The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
Study NCT04318522 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulator
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
Study NCT04318522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
Study NCT04151160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound measurements
Description: i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
Study NCT02556294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance based intervention
Description: The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
Study NCT02556294 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HIV/STI counseling and testing
Description: The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
Study NCT02556294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STI counseling and testing
Description: The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
Study NCT04315025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Description: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
Study NCT04315025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditioned Medium (CM)
Description: Conditioned Medium (CM) injected by peribulbar
Study NCT01030978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Bodies Healthy Lifestyle Program
Description: Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
Study NCT01030978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
Study NCT01138930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 1.5g daily for 3 month
Study NCT01138930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily
Study NCT03221062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser en Bloc Resection
Description: Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
Study NCT00421525 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: milatuzumab
Description: twice weekly dosing for 4 weeks, total of 8 doses
Study NCT02768948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan during 6 months
Description: telmisartan during 6 months
Study NCT02768948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan during 6 months
Description: Losartan during 6 months
Study NCT02768948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study NCT02176421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLBELLA® with lidocaine
Description: VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
Study NCT03430063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDREGN2810
Description: Standard dose intravenous (IV) infusion
Study NCT03430063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDREGN2810/ipi
Description: Combination therapy dose IV
Study NCT03430063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDREGN2810
Description: High dose IV
Study NCT02268617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
Study NCT01057615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
Study NCT01057615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
Study NCT01057615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Placebo
Description: 10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
Study NCT01057615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid Placebo
Description: 2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
Study NCT05099913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deanxit
Description: Central neuromodulators was applied in refractory FD patients for different time
Study NCT04315103 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
Description: All the injections were done by the same experienced physician using aseptic procedures.
Study NCT04315103 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
Description: All the injections were done by the same experienced physician using aseptic procedures.
Study NCT01496534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
Study NCT01496534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
Study NCT00103337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT00103337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01427192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: 250 mg bid
Study NCT01427192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Oxygen deliverded by nasal cannula
Study NCT01427192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Bi-level non-invasive ventilation via nasal mask
Study NCT01427192 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: Room air applied via sham oxygen concentrator
Study NCT01427192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (Mannitol) similar to acetazolamide
Study NCT03038984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At Home Screening procedure On demand
Description: Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
Study NCT03038984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At Home Screening procedure every 3 months
Description: Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
Study NCT03327402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.